RegulatoryCompany release

Candel delays prostate cancer BLA to mid-2027 as it refines assay with FDA

🇺🇸 Candel Therapeutics, Inc. (CADL) · Thu 12 Nov 2026

Candel Therapeutics now expects to file its aglatimagene besadenovec application in mid-2027, citing assay refinement timelines, and reports cash of $203.1 million.

Candel Therapeutics has pushed back its planned Biologics License Application (BLA) for aglatimagene besadenovec in localised prostate cancer to mid-2027. The company announced the revised timing with its third-quarter 2026 results on 12 November 2026.

Candel attributes the new timeline to assay refinement and says it is in discussions with the US Food and Drug Administration (FDA). The summary of the release does not specify which assay is involved or what changes are being discussed.

The company reported $203.1 million in cash, which it says is enough to fund operations into the second quarter of 2028. It also presented new biomarker data for aglatimagene and a second candidate, linoserpaturev, at the Society for Immunotherapy of Cancer (SITC) meeting.

On manufacturing, Candel described process validation batches at its contract development and manufacturing organisation (CDMO). These batches are intended for commercial use if the BLA is approved.

What it means for your team

  • Assay refinement is cited as the driver of the delay, so analytical readiness can shape BLA timing for biologic products, particularly where biomarker or potency testing is involved.
  • Regulatory teams tracking aglatimagene should plan around a mid-2027 submission rather than the earlier timeline.
  • Process validation batches intended for commercial supply show manufacturing preparation is under way ahead of any approval.

Company's press release (SEC filing): Candel Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Candel Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →